Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6777)
All Articles published online
|
Publishing Process of This Article
|
Dec 16, 2014 (publication date) through May 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Inno A, Fanetti G, Bartolomeo MD, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. World J Clin Cases 2014; 2(12): 835-839 [PMID: 25516857 DOI: 10.12998/wjcc.v2.i12.835] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v2/i12/835.htm |
| Number | Citing Articles |
| 1 |
Dan Gao, James G. Herman, Mingzhou Guo. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget 2016; 7(24): 37331 doi: 10.18632/oncotarget.7949
|
| 2 |
Latha M. Malaiyandi, Lawrence A. Potempa, Nicholas Marschalk, Paiboon Jungsuwadee, Kirk E. Dineley. Apoptosis and Beyond. 2018; : 427 doi: 10.1002/9781119432463.ch21
|
| 3 |
Zoran Gatalica, Semir Vranic, Joanne Xiu, Jeffrey Swensen, Sandeep Reddy. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer 2016; 15(3): 405 doi: 10.1007/s10689-016-9884-6
|
| 4 |
Sandra Mersakova, Katarina Janikova, Michal Kalman, Juraj Marcinek, Marian Grendar, Martin Vojtko, Roman Kycina, Miroslav Pindura, Jan Janik, Peter Mikolajcik, Eva Gabonova, Ludovit Laca, Ester Mejstrikova, Erika Halasova, Jan Strnadel, Zora Lasabova. Cancer stem cell marker expression and methylation status in patients with colorectal cancer. Oncology Letters 2022; 24(1) doi: 10.3892/ol.2022.13352
|
| 5 |
Filippo Pietrantonio, Filippo de Braud, Massimo Milione, Claudia Maggi, Roberto Iacovelli, Katia Fiorella Dotti, Federica Perrone, Elena Tamborini, Marta Caporale, Rosa Berenato, Giorgia Leone, Alessio Pellegrinelli, Ilaria Bossi, Fabrizio Festinese, Stefano Federici, Maria Di Bartolomeo. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. Targeted Oncology 2016; 11(3): 337 doi: 10.1007/s11523-015-0397-2
|
| 6 |
Zachary D. Nagel, Andrew A. Beharry, Patrizia Mazzucato, Gaspar J. Kitange, Jann N. Sarkaria, Eric T. Kool, Leona D. Samson, Brendan D Price. Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells. PLOS ONE 2019; 14(2): e0208341 doi: 10.1371/journal.pone.0208341
|
| 7 |
Michele Ghidini, Nicola Fusco, Massimiliano Salati, Shelize Khakoo, Gianluca Tomasello, Fausto Petrelli, Dario Trapani, Angelica Petrillo. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Current Drug Targets 2021; 22(9): 1021 doi: 10.2174/1389450122666210204204415
|
| 8 |
M A Calegari, A Inno, S Monterisi, A Orlandi, D Santini, M Basso, A Cassano, M Martini, T Cenci, I de Pascalis, F Camarda, B Barbaro, L M Larocca, S Gori, G Tonini, C Barone. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. British Journal of Cancer 2017; 116(10): 1279 doi: 10.1038/bjc.2017.109
|
| 9 |
L. Barault, A. Amatu, F.E. Bleeker, C. Moutinho, C. Falcomatà, V. Fiano, A. Cassingena, G. Siravegna, M. Milione, P. Cassoni, F. De Braud, R. Rudà, R. Soffietti, T. Venesio, A. Bardelli, P. Wesseling, P. de Witt Hamer, F. Pietrantonio, S. Siena, M. Esteller, A. Sartore-Bianchi, F. Di Nicolantonio. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology 2015; 26(9): 1994 doi: 10.1093/annonc/mdv272
|
| 10 |
Julia Krushkal, Simarjeet Negi, Laura M. Yee, Jason R. Evans, Tanja Grkovic, Alida Palmisano, Jianwen Fang, Hari Sankaran, Lisa M. McShane, Yingdong Zhao, Barry R. O'Keefe. Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products. Molecular Oncology 2021; 15(2): 381 doi: 10.1002/1878-0261.12849
|
| 11 |
Khatere Mokhtari, Maryam Peymani, Mohsen Rashidi, Kiavash Hushmandi, Kamran Ghaedi, Afshin Taheriazam, Mehrdad Hashemi. Colon cancer transcriptome. Progress in Biophysics and Molecular Biology 2023; : 49 doi: 10.1016/j.pbiomolbio.2023.04.002
|
| 12 |
Riccardo Ricci, Maurizio Martini, Gloria Ravegnini, Tonia Cenci, Massimo Milione, Paola Lanza, Francesco Pierconti, Donatella Santini, Sabrina Angelini, Alberto Biondi, Fausto Rosa, Sergio Alfieri, Gennaro Clemente, Roberto Persiani, Alessandra Cassano, Maria A. Pantaleo, Luigi M. Larocca. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. Clinical Epigenetics 2019; 11(1) doi: 10.1186/s13148-018-0594-9
|
| 13 |
Filippo Pietrantonio, Giovanni Randon, Dario Romagnoli, Samantha Di Donato, Matteo Benelli, Filippo de Braud. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. Cancer Treatment Reviews 2020; 82: 101935 doi: 10.1016/j.ctrv.2019.101935
|
| 14 |
Sepideh Shahkarami, Samaneh Zoghi, Nima Rezaei. Cancer Immunology. 2020; : 491 doi: 10.1007/978-3-030-30845-2_22
|
| 15 |
Ningning Zhao, Chuanxi Lai, Yunfei Wang, Sheng Dai, Hongcang Gu. Understanding the role of DNA methylation in colorectal cancer: Mechanisms, detection, and clinical significance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2024; 1879(3): 189096 doi: 10.1016/j.bbcan.2024.189096
|
| 16 |
Siqi Fu, Haijing Wu, Huiming Zhang, Christine G. Lian, Qianjin Lu. DNA methylation/hydroxymethylation in melanoma. Oncotarget 2017; 8(44): 78163 doi: 10.18632/oncotarget.18293
|
| 17 |
Érica S. S. de Araújo, Dimitrius T. Pramio, André Y. Kashiwabara, Paula C. Pennacchi, Silvya S. Maria-Engler, Maria I. Achatz, Antonio H. J. F. M. Campos, João P. Duprat, Carla Rosenberg, Dirce M. Carraro, Ana C. V. Krepischi. DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/376423
|
| 18 |
Giuseppina Improta, Cathrin Ritter, Angela Pettinato, Valeria Vasta, David Schrama, Filippo Fraggetta, Jürgen C. Becker. MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo. Journal of Cancer Research and Clinical Oncology 2017; 143(8): 1489 doi: 10.1007/s00432-017-2413-7
|
| 19 |
Csaba T�th, Farkas S�k�sd, Erzs�bet Valicsek, Esther Herpel, Peter Schirmacher, L�szl� Tiszlavicz. Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.7756
|
| 20 |
Yue Zhao, Fei Feng, Qing-Hong Guo, Yu-Ping Wang, Rui Zhao. Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors. World Journal of Gastroenterology 2020; 26(34): 5074-5089 doi: 10.3748/wjg.v26.i34.5074
|
| 21 |
Barbara Pasculli, Raffaela Barbano, Paola Parrella. Epigenetic Mechanisms in Cancer. 2018; : 275 doi: 10.1016/B978-0-12-809552-2.00011-5
|